Announcements
- Gritstone bio Reports Third Quarter 2023 Financial Results and Provides Corporate Updates
- Presentations at IDWeek 2023 Highlight Potentially Differentiated Immunogenicity of Gritstone bio’s Next Generation COVID-19 Vaccine
- Gritstone bio Awarded BARDA Contract to Conduct Comparative Phase 2b Study Evaluating Next-Generation Vaccine Candidate for COVID-19 Valued at up to $433 Million
Key statistics
As of last trade Gritstone bio Inc (2JQ:MUN) traded at 0.701, 1.15% above its 52-week low of 0.693, set on Apr 16, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 0.701 |
---|---|
High | 0.701 |
Low | 0.701 |
Bid | 0.6815 |
Offer | 0.7015 |
Previous close | 0.702 |
Average volume | 1.03k |
---|---|
Shares outstanding | 105.92m |
Free float | 103.48m |
P/E (TTM) | -- |
Market cap | 78.23m USD |
EPS (TTM) | -1.55 USD |
Data delayed at least 15 minutes, as of Apr 24 2024 07:06 BST.
More ▼